ライフサイエンスコーパス: clinical improvement

1 ed in rapid defervescence (median, 4 hr) and clinical improvement.

2 umulation within the CNS and failed to drive clinical improvement.

3 ree had normalization of T-cell function and clinical improvement.

4 eater severity and a 25% reduction indicates clinical improvement.

5 activity was associated with death and poor clinical improvement.

6 showed a linear univariate correlation with clinical improvement.

7 can discontinue inotropic therapy because of clinical improvement.

8 ease phenotype and to correlate changes with clinical improvement.

9 x patients resulted in changes suggestive of clinical improvement.

10 patient, whereas 5 of 6 patients with it had clinical improvement.

11 apeutic factor IX expression associated with clinical improvement.

12 subgenual connectivity predicted subsequent clinical improvement.

13 s between disease biomarkers in the skin and clinical improvement.

14 transient elastography, which decreased with clinical improvement.

15 the up-grade to CRT-D resulting in enormous clinical improvement.

16 ed on disease-specific targets have shown no clinical improvement.

17 ater in childhood, without any corresponding clinical improvement.

18 ssed associations between MRI parameters and clinical improvement.

19 fixed defect size, regional wall motion, and clinical improvement.

20 -1F6, -1F8, and -1F9 mRNAs, concomitant with clinical improvement.

21 relief of anatomic obstruction and sustained clinical improvement.

22 L-1Ra, anakinra, and experienced significant clinical improvement.

23 serine treatment may underlie the associated clinical improvement.

24 an inflammatory epitope might translate into clinical improvement.

25 reatment initiation and the delayed onset of clinical improvement.

26 tcomes in terms of faster and more extensive clinical improvement.

27 toxic metabolic pathways but may not hasten clinical improvement.

28 he anterior attentional network and encumber clinical improvement.

29 They returned for a follow-up scan after clinical improvement.

30 was associated with a higher probability of clinical improvement.

31 subjects worsened, and seven subjects showed clinical improvement.

32 ssociations of treatment with probability of clinical improvement.

33 hat were associated with high probability of clinical improvement.

34 anzapine showed a less consistent profile of clinical improvement.

35 nalyzed for associations with probability of clinical improvement.

36 The SPWMD did not correlate with measures of clinical improvement.

37 rapy does not correlate with hemodynamic and clinical improvement.

38 llent collateral blood vessels formation and clinical improvement.

39 h l-dopa and STN stimulation correlated with clinical improvement.

40 able axonal regeneration, remyelination, and clinical improvement.

41 treatment with MEDI2070 were associated with clinical improvement.

42 ivocally shown to result in histological and clinical improvement.

43 e cost-effective and demonstrate significant clinical improvement.

44 he active DBS contacts to it correlated with clinical improvement.

45 21 months after IRIS accompanied by delayed clinical improvement.

46 rapy was not significantly associated with a clinical improvement.

47 osporine, resulting in rapid and significant clinical improvement.

48 levels in patients and can lead to striking clinical improvement.

49 us wild-type channels may confer significant clinical improvement.

50 ts with bronchoscopic vapour ablation led to clinical improvement.

51 presumably limiting NIr exposure and overall clinical improvement.

52 cyclosporine resulted in rapid and sustained clinical improvement.

53 dren hospitalized for bronchiolitis who show clinical improvement.

54 " pulse oximetry readings for those who show clinical improvement.

55 f phototherapy in patients showing excellent clinical improvement.

56 The povidone-iodine group had the highest clinical improvements.

57 determine whether these effects translate to clinical improvements.

58 Both treatments resulted in significant clinical improvements.

59 At review, 15 patients were alive and had clinical improvement, 18 had died of comorbid causes, on

60 nge in management 57.7% (45.9% to 69.1%) and clinical improvement 36.6% (26.3% to 47.5%).

61 wo achieved complete remission, 7 partial, 1 clinical improvement, 4 stable disease, and 3 had progre

62 (n = 90), had significantly higher rates of clinical improvement (56.8% vs 28.2%; chi21 = 13.09, P <

63 as common but not universal in non-CLIPPERS [clinical improvement (8/12); radiological improvement (2

64 All individual macaques showed clinical improvement after hRPE cell implantation compar

65 Case reports provided examples of clinical improvement after PTRAS in patients with acute

66 The group of patients showing no clinical improvement after rituximab therapy were distin

67 g a JAK-activating CSF3R mutation had marked clinical improvement after the administration of the JAK

68 strengthening with or without NMES enhances clinical improvement after TKA, achieving similar short-

69 Clinical improvement after transplantation correlated wi

70 One patient showed a rapid clinical improvement after treatment with rituximab alon

71 Clinical improvements after CBT-I were correlated with B

72 most patients with a decline in CSF BDG had clinical improvement, all 3 patients with continually el

73 4 days of treatment initiation, progressive clinical improvement allowed weaning from extracorporeal

74 caine nonuse days and associated measures of clinical improvement among cocaine-dependent individuals

75 een the reduction of anti-MAG IgM levels and clinical improvement, an immunological surrogate mouse m

76 18 eyes (81.9%) showed clinical improvement and 4 (18.1%) had decreased SEI whi

77 ed medication for hypertension, demonstrated clinical improvement and amelioration of fibrosis in the

78 The patient did not have any clinical improvement and eventually died after the famil

79 hat lithium plus OPT would result in greater clinical improvement and fewer necessary clinical adjust

80 ation cephalosporins is associated with slow clinical improvement and high relapse burden for enteric

81 topoietic stem cell transplantation reported clinical improvement and inflammatory stabilization in t

82 if these physiologic benefits translate into clinical improvement and outweigh the risk of transfusio

83 sm through which these interventions lead to clinical improvement and potential differences in networ

84 At 1 year, the patient demonstrated good clinical improvement and results of follow-up CSF cultur

85 Capsulotomy and DBS lead to similar clinical improvement and similar metabolic network chang

86 orary) combination therapy results in faster clinical improvement and targeted treatment determines l

87 Two patients presented no clinical improvement and the remaining one experienced a

88 o myositis antibody-negative patients showed clinical improvement and tolerated lower doses of cortic

89 cause the determinants of ADE are markers of clinical improvement and/or of lower risk of treatment f

90 unt clinical outcomes, coordination of care, clinical improvement, and electronic information exchang

91 sociated with correction of dysbiosis, rapid clinical improvement, and healing of enterocolitis.

92 gest that this approach is safe and leads to clinical improvement, and larger scale randomised contro

93 uced improvements in MF-SB were annotated as clinical improvement, anemia response, spleen response,

94 Abs are recorded, the mechanisms that convey clinical improvement are incompletely understood.

95 shows promise, but the mechanisms underlying clinical improvement are unknown.

96 ver, the neural substrates that underlie the clinical improvements are not well understood.

97 However, some trials have reported clinical improvement as early as the first week of treat

98 fter MitraClip procedure are associated with clinical improvement as measured by 6MWT.

99 ave failed to yield robust immune-correlated clinical improvements as observed in animal models, fuel

100 sgACC and the default mode network predicted clinical improvement, as did more positive amygdala-to-v

101 ity and the antimicrobial treatment regimen, clinical improvement at 1 week (corrected risk ratios [c

102 Clinical improvement at 1 y was relatively better for th

103 sirolimus-eluting stent results in continued clinical improvement at 1 year after initial implantatio

104 at a daily dose of 4 mg was associated with clinical improvement at 12 weeks.

105 TNF-alpha significantly correlated with the clinical improvement at 16 wk, suggesting that these lev

106 magnetic resonance imaging and the extent of clinical improvement at 24 hours as assessed on the Nati

107 ssed for clinical outcome, 59 (57%) reported clinical improvement at the last study visit, 23 (22%) w

108 The rates of clinical improvement at week 8 among patients given 9 mg

109 adjuvant Povidone-iodine led to significant clinical improvements at implants.

110 adjuvant povidone-iodine led to significant clinical improvements at implants.

111 hs), (2) improvement of quality of life, (3) clinical improvement (at least 1 Rutherford category), a

112 and intravenous immunoglobulin, resulting in clinical improvement before chemotherapy.

113 activity after treatment and correlates with clinical improvements better than hematologic response.

114 Foxp3(GFP+) Tregs did not elicit additional clinical improvement but conversely delayed reconstituti

115 for 1 - 13 months; while the eyes which had clinical improvement but had not CSIS score 0 (4 eyes) w

116 ceiving clozapine with evidence of sustained clinical improvement, but additional adverse events emer

117 PRP) has been shown to result in substantial clinical improvements, but the long-term effects of this

118 At 12 months, clinical improvement by >/=1 Rutherford category without

119 SRIs rather than placebo was associated with clinical improvement by the end of the first week of use

120 Clinical improvements can be maintained over long period

121 remission (CR), partial remission (PR), and clinical improvement (CI).

122 ing techniques are used in younger patients, clinical improvements, comparable to older adult patient

123 t of suprabony defects may lead to a greater clinical improvement compared to SPPF alone.

124 usual group (22 subjects) showed significant clinical improvement compared with the treatment-as-usua

125 + EDTA-treated sites showed more significant clinical improvements compared to DOX-beta-TCP-treated s

126 ase in stroke volume translated into greater clinical improvements compared to patients receiving sim

127 tion of L. rhamnosus SP1 resulted in similar clinical improvements compared with SRP alone.

128 Conversely, clinical improvement correlated inversely with metabolic

129 Clinical improvement correlated with 90-min norketamine

130 A common clinical improvement criterion of -20% or -5 modified Ro

131 flash bother, recorded on daily diaries, and clinical improvement (defined as hot flash frequency >/=

132 of heart failure patients do not demonstrate clinical improvement despite cardiac resynchronization t

133 how long-term persistence of JCV and delayed clinical improvement despite inflammation.

134 zole use was not associated with significant clinical improvement despite uniform correction of perip

135 ticipants experienced a comparable degree of clinical improvement, despite receiving fewer treatment

136 rtial response and nine patients (22.5%) had clinical improvement durable for a median of 18 months (

137 nitiates LV reverse remodeling, and provides clinical improvement during 6 months after treatment.

138 Biomarkers predicting the likelihood of clinical improvement during immunotherapy would signific

139 f view, both patients showed biochemical and clinical improvement during the 6 month follow-up and th

140 Clinical improvement followed removal of the allograft a

141 d and guanine measured at baseline predicted clinical improvement following four weeks of treatment w

142 nto the molecular mechanisms associated with clinical improvement following NILT.

143 study, data suggest that tooth retention and clinical improvements following GTR treatment of intrabo

144 gG1 mAb, results in beneficial, yet limited, clinical improvement for patients with head and neck (HN

145 reduction of emphysematous lobes results in clinical improvement for patients with severe emphysema.

146 ve, well-tolerated treatment providing clear clinical improvements for fludarabine-refractory patient

147 s with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthr

148 s disease support lytic replication, so that clinical improvement frequently occurs in response to tr

149 BI 655066 was associated with clinical improvement from week 2 and maintained for up t

150 ditis had higher likelihood of delisting for clinical improvement (hazard ratio, 2.49 [95% confidence

151 tation of riboflavin can lead to significant clinical improvement if started early in the disease pro

152 Successful treatment (clinical improvement; improved follow-up markers and ima

153 ne pathway that signals through STAT3 led to clinical improvement in 1 patient, suggesting a potentia

154 Low-dose IL-2 provides durable clinical improvement in active cGVHD and extended therap

155 ded by International Working Group criteria (clinical improvement in all cases): reduction in spleen

156 Cessation of treatment led to clinical improvement in all cases.

157 Despite clinical improvement in all patients, there was a residu

158 in leads to sustained clearance of virus and clinical improvement in approximately 50% of patients.

159 The primary outcome was clinical improvement in asthma control over 3 months.

160 Clinical improvement in depressive patients was predicte

161 ion inducement correlates with the degree of clinical improvement in essential tremor.

162 trong correlation between decrease in FA and clinical improvement in hand tremor 3 months after lesio

163 as a close correlation between the degree of clinical improvement in individual patients and reductio

164 Clinical improvement in individuals with PTSD was associ

165 Tildrakizumab demonstrated important clinical improvement in moderate-to-severe psoriasis pat

166 fects of dopamine enhancers, which predicted clinical improvement in motor and motivational deficits.

167 ogation of inflammatory pathways accompanied clinical improvement in multiple studies suggesting that

168 A clinical improvement in nasal allergic symptoms upon cha

169 uded: asymptomatic intracerebral hemorrhage; clinical improvement in NIHSS; and 90-day modified Ranki

170 reatment with triheptanoin resulted in a 90% clinical improvement in non-epileptic paroxysmal manifes

171 Technical success did not result in clinical improvement in one patient.

172 mechanical debridement resulted in dramatic clinical improvement in patients (>50% smokers) with gen

173 ls of the colonic lamina propria accompanied clinical improvement in patients receiving anti-interleu

174 MP-8 levels decreased together with observed clinical improvement in patients with gingivitis.

175 ociated with rapid, substantial, and durable clinical improvement in patients with moderate-to-severe

176 and TNF-alpha antagonists may contribute to clinical improvement in patients with psoriasis by impro

177 treatment with rituximab was associated with clinical improvement in patients with refractory ophthal

178 ssue macrophages is a reliable biomarker for clinical improvement in patients with rheumatoid arthrit

179 ies and demonstrates that rapamycin provides clinical improvement in patients with venous malformatio

180 ession of RF may not be sufficient to induce clinical improvement in RA.

181 fatigue response to mild exercise would show clinical improvement in response to treatment strategies

182 quire corticosteroids and showed significant clinical improvement in scores for pain, stiffness, and

183 itive pressure ventilation have demonstrated clinical improvement in studies of patients refractory t

184 r 16 weeks, we showed a significant pre-post clinical improvement in the DHA group versus placebo, us

185 ll four surviving cohort members experienced clinical improvement in the first decade of life.

186 Most patients experienced substantial clinical improvement in their atopic dermatitis.

187 Cumulative rates of clinical improvement in these patients were 78% in the 5

188 rm morphology and their loss correlated with clinical improvement in treated patients.

189 r in the second study correlated with marked clinical improvements in motor functions.

190 Brodalumab treatment resulted in significant clinical improvements in patients with moderate-to-sever

191 ults demonstrated that both groups displayed clinical improvements in PD and CAL that were sustained

192 l operators provided similar average durable clinical improvements in postoperative pain and disabili

193 Oxypurinol did not produce clinical improvements in unselected patients with modera

194 Some of the barriers to clinical improvements include the systemic toxicity of c

195 molecular diagnostic test led to significant clinical improvements including reduced time to initiati

196 The response to ICSs was based on clinical improvements, including a 12% or greater increa

197 biopsy of an inflamed knee before and after clinical improvement induced by methotrexate.

198 Clinical improvement is accompanied by decreases in numb

199 clinical response to omalizumab and whether clinical improvement is associated with either mast cell

200 While clinical improvement is nearly universal in these patien

201 ncentration is <200 mg/L or 6.2 mmol/L and a clinical improvement is observed.

202 wing surgery, but it is unclear whether this clinical improvement is related to an improvement in OR

203 tionnaires, clinical photography, subjective clinical improvement, light microscopy, melanin index, r

204 onse (entrainment at month 1 or month 7 plus clinical improvement, measured by the Non-24 Clinical Re

205 necteplase was associated with greater early clinical improvement (median National Institutes of Heal

206 ecteplase-treated patients had greater early clinical improvement (median National Institutes of Heal

207 ockade, but did not result in neuropathic or clinical improvements, most likely due to the late start

208 dentify connections reliably associated with clinical improvement (motor score of the Unified Parkins

209 The clinical improvement observed after training might be me

210 This study demonstrated that the clinical improvements observed with the DEX implant were

211 ions, the present findings indicate that the clinical improvements obtained with regenerative surgery

212 Some clinical improvement occurred in both groups of patients

213 Clinical improvement occurred when vemurafenib therapy w

214 Marked clinical improvement occurred within 6 weeks of initiati

215 and mortality, and postoperative subjective clinical improvement occurs irrespective of age at surge

216 heumatology (ACR) 20 responses (indicating a clinical improvement of 20 percent or greater) and impro

217 rapies that reduce sebum excretion result in clinical improvement of acne.

218 risk" infants and to increasing survival and clinical improvement of affected infants.

219 cell transplantation and demonstrated marked clinical improvement of all IBD-associated clinical symp

220 sis Research and Treatment (IWG-MRT)-defined clinical improvement of anemia in 8 (19%) and/or decreas

221 e pump function, compounded by a significant clinical improvement of CVD.

222 The clinical improvement of most patients indicates that ant

223 sia as well as high myopia, with evidence of clinical improvement of motor function over time in the

224 Clinical improvement of psoriasis induced by IL-4 treatm

225 ly reduced macrophages in the skin, although clinical improvement of scleroderma was only seen in one

226 insomnia treatment response-that is, marked clinical improvement of symptoms by the Pittsburgh Sleep

227 rct glial scar may contribute to the limited clinical improvement often observed after ischemic brain

228 Also, clinical improvement on subsequent days may have little

229 studies will hopefully provide evidence for clinical improvement on the basis of altering treatment

230 ared with those receiving placebo in overall clinical improvements or limitations in work or other ac

231 connectivity were independent predictors of clinical improvement (p < 0.001) and estimated response

232 th both interventions, which correlated with clinical improvement (P < 0.05).

233 henylalanine levels returned to normal, with clinical improvement (P = 0.0002).

234 groups had greater reperfusion (P=0.004) and clinical improvement (P<0.001) at 24 hours than the alte

235 l DHE were all significantly associated with clinical improvement (P<0.01 for all).

236 ites, whereas adjacent sites presented small clinical improvements (P <0.001).

237 Clinical improvement persisted more than 2 weeks followi

238 ed human autoimmune disease, with high-level clinical improvements possible in approximately 90% of p

239 from 11 US health systems participated in a clinical improvement project based on previously describ

240 A 4-year clinical improvement project was performed in a multispe

241 Clinical improvement projects included total hip and kne

242 improvement methods that are widely used in clinical improvement projects, and were supported in the

243 ults serve as a possible basis for the small clinical improvement seen in autologous BM cell therapy

244 ilar response patterns could account for the clinical improvement seen in inflammatory bowel disease

245 luting stent to document whether the initial clinical improvement seen in previous smaller series is

246 we found that only patients with significant clinical improvement showed a significant decrease of pr

247 mab were not associated with any evidence of clinical improvement, so thalidomide and dexamethasone w

248 correlation was found between Treg cells and clinical improvement, suggesting that increases in Treg

249 is, importantly, associated with significant clinical improvement, suggesting that SA promotes the di

250 Marked clinical improvement suggests that eculizumab may be a l

251 le rheumatoid arthritis (JRA) provided rapid clinical improvement that was sustained for up to 2 year

252 Here, we focus on clinical improvements that have been achieved with techn

253 ted with BRAFis initially exhibit measurable clinical improvement, the majority of patients eventuall

254 focal regions of seizure onset can result in clinical improvement, the molecular mechanisms that prod

255 atients in both treatment groups experienced clinical improvement, the study did not meet its primary

256 eks of risperidone treatment and significant clinical improvement, this pretreatment impairment worse

257 in stroke; however, the utility of measuring clinical improvement to assess artery status has not bee

258 ients with severe asthma fail to demonstrate clinical improvement upon glucocorticoid therapy, and th

259 Although resulting in a significant clinical improvement, UV-A1 phototherapy was inferior to

260 4+ T-cell count returned to baseline and the clinical improvement waned, possibly due to the patient'

261 Clinical improvement was accompanied by a significant re

262 Clinical improvement was accompanied by significant redu

263 Clinical improvement was assessed by monitoring the tape

264 Clinical improvement was associated with expansion of CD

265 Clinical improvement was evident as early as 4 weeks aft

266 At 40-week treatment, clinical improvement was found significant by both SARA

267 Clinical improvement was greater in patients taking teri

268 Side effects were short-lived, and clinical improvement was maintained for up to 6 weeks wi

269 ed that the effects of DCS administration on clinical improvement was moderated by the level of fear

270 Clinical improvement was more common with older age at s

271 Clinical improvement was observed for 10 of 11 mediator

272 women; median age, 42 [range, 18-69] years), clinical improvement was observed in parallel with compl

273 alis continua on January 16, 2013, a gradual clinical improvement was observed until March.

274 Clinical improvement was obtained after introduction of

275 Nonetheless, clinical improvement was significant only in younger (ag

276 Clinical improvements were associated with significant g

277 Clinical improvements were consequently noted, though th

278 These clinical improvements were correlated with reduced accum

279 Correlations with clinical improvements were investigated using the Yale-B

280 n provide incremental information to predict clinical improvement when added to clinical factors and

281 The clinical improvement with 'stimulation on' compared to '

282 lidation yielded a categorical prediction of clinical improvement with 81% accuracy, 84% sensitivity

283 Our primary outcome was clinical improvement with anti-inflammatory therapy.

284 inflammation the patient demonstrated rapid clinical improvement with conservative treatment.

285 gs that SPWMD predicts reverse remodeling or clinical improvement with CRT were not reproducible in p

286 Unexpectedly, transient clinical improvement with fever was noted in 6 patients.

287 rophysiological characterization of observed clinical improvement with fever.

288 and thalidomide each have led to significant clinical improvement with fewer side effects than result

289 eek 12 in the NRs was associated with a late clinical improvement with infliximab treatment (24 weeks

290 Previous research suggested clinical improvement with inhibition of interleukin 23 p

291 ts (titer range, 1:10 to >/=1:2,560), due to clinical improvement with targeted therapy and decreasin

292 Findings were consistent with clinical improvements with CZP plus MTX in both trials.

293 Fourteen patients (93.3%) showed a clinical improvement, with 13 (86.6%) achieving a scleri

294 All 6 evaluable patients exhibited major clinical improvement, with muscle strength increasing ov

295 All 4 patients demonstrated striking clinical improvement within 1 month of the initiation of

296 the inflammation and resulted in significant clinical improvement within a few days.

297 ptor antagonist ketamine produced meaningful clinical improvement within hours, suggested that rapid-

298 Both treatments produced significant clinical improvements within the groups.

299 t of targeted therapy resulting in long-term clinical improvement without nonspecific immune suppress

300 nfliximab administration was associated with clinical improvement without significant adverse events